Since January 2020, Elsevier has established a COVID-19 resource center on its public news and information website, Elsevier Connect, providing free information in English and Mandarin about the novel coronavirus. Elsevier has granted permission to make all its COVID-19-related research available in PubMed Central and other public repositories, allowing unrestricted reuse and analysis with acknowledgment of the original source. The article by Fatima Amanat and Florian Krammer discusses therapeutic and prophylactic interventions for SARS-CoV-2, focusing on vaccine development and its challenges. The authors highlight the rapid development of vaccines but note that they may come too late to affect the first wave of a potential pandemic. They emphasize the importance of SARS-CoV-2 vaccines in reducing morbidity and mortality if the virus establishes itself in the population. The article also reviews the history of coronaviruses, vaccine technology, and the current pipeline for SARS-CoV-2 vaccines, including various vaccine platforms such as mRNA, recombinant protein, viral vector, and inactivated virus vaccines. The authors discuss the challenges and considerations in vaccine development, such as waning antibody responses and the need for vaccines that protect older individuals. They conclude by emphasizing the importance of investing in vaccine production infrastructure to respond quickly to emerging viruses and the potential for vaccines to be useful in future waves of the pandemic or as seasonal vaccines.Since January 2020, Elsevier has established a COVID-19 resource center on its public news and information website, Elsevier Connect, providing free information in English and Mandarin about the novel coronavirus. Elsevier has granted permission to make all its COVID-19-related research available in PubMed Central and other public repositories, allowing unrestricted reuse and analysis with acknowledgment of the original source. The article by Fatima Amanat and Florian Krammer discusses therapeutic and prophylactic interventions for SARS-CoV-2, focusing on vaccine development and its challenges. The authors highlight the rapid development of vaccines but note that they may come too late to affect the first wave of a potential pandemic. They emphasize the importance of SARS-CoV-2 vaccines in reducing morbidity and mortality if the virus establishes itself in the population. The article also reviews the history of coronaviruses, vaccine technology, and the current pipeline for SARS-CoV-2 vaccines, including various vaccine platforms such as mRNA, recombinant protein, viral vector, and inactivated virus vaccines. The authors discuss the challenges and considerations in vaccine development, such as waning antibody responses and the need for vaccines that protect older individuals. They conclude by emphasizing the importance of investing in vaccine production infrastructure to respond quickly to emerging viruses and the potential for vaccines to be useful in future waves of the pandemic or as seasonal vaccines.